Business / Finance

RSS

Althea extends labeling, packaging of biological product services through Sherpa

Althea Technologies, Inc. announced today that it has extended its service offering to include labeling, packaging, storage and distribution of drug and biological products through its co-marketing partner, Sherpa Clinical Packaging.

25 Mar 2011

Accretive Health prices public offering of 6,500,000 shares of common stock

Accretive Health, Inc., a leading provider of services that help healthcare providers generate sustainable improvements in their operating margins and healthcare quality while also improving patient, physician and staff satisfaction, today announced the pricing of the public offering of 6,500,000 shares of its common stock at a price to the public of $23.50 per share.

25 Mar 2011

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

Boehringer Ingelheim formally acquires Amgen's Fremont manufacturing site

Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California. This acquisition involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site.

25 Mar 2011

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

AltheRx Inc., a privately-held clinical development company, announced today that it has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in Phase II clinical programs for the treatment of Overactive Bladder in women and Irritable Bowel Syndrome.

25 Mar 2011

Conmed fourth quarter net revenues increase 12.6% to $15.8 million

Conmed Healthcare Management, Inc. today announced financial results for its fourth quarter and year ended December 31, 2010.

24 Mar 2011

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.

24 Mar 2011

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics.

24 Mar 2011

DATATRAK fourth quarter revenue increases to 38%

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the fourth quarter and full year of 2010.

22 Mar 2011

EMD Millipore to acquire Biotest microbiology business to expand product portfolio

EMD Millipore, the Life Science division of Merck KGaA of Germany, today announced plans to expand its industrial microbiological testing portfolio. This follows Merck KGaA's announcement it has entered into a definitive agreement to acquire the microbiology business of Germany-based Biotest AG.

22 Mar 2011

Gerresheimer acquires Vedat

Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, has acquired the Brazilian company Vedat to strengthen its pharmaceutical plastic packaging business in South America.

22 Mar 2011

Menicon opens new contact lens R&D and manufacturing facility in Singapore

Menicon Singapore, a subsidiary of Menicon Co., Ltd., Japan's first and largest contact lens manufacturer, has opened its new R&D and manufacturing facility.

22 Mar 2011

Publicis Groupe agrees to acquire majority stake in India-based Watermelon

Publicis Groupe announced today that it has agreed to acquire a majority stake in a leading healthcare advertising agency in Mumbai, India-Watermelon Healthcare Communications Private Limited.

22 Mar 2011

Cephalon to acquire Gemin X Pharmaceuticals

Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.

22 Mar 2011

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

China PharmaHub Corp., a biopharmaceutical acquisition and development company, today announced that it has signed a exclusive worldwide license agreement with the University of California, for worldwide rights to develop, commercialize and market a universal donor blood product derived from embryonic stem cells developed by UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa Carrier.

21 Mar 2011

Premier healthcare alliance named one of World's Most Ethical Companies for 2011

The Premier healthcare alliance has been named one of the Ethisphere Institute's 2011 World's Most Ethical Companies for the fourth year in a row. Ethisphere selected Premier from a record number of applicants across the globe.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

AOBO board announces $20 million share buyback program

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, announced at its 2010 earnings conference call, held on March 15, 2011, that its board of directors authorized a share buyback program for the repurchase of up to $20 million of the Company's outstanding common stock over the next two years.

21 Mar 2011

CardioFocus secures $5M in debt financing from Silicon Valley Bank

CardioFocus, a venture capital-backed medical device company developing technology to treat cardiac disorders, has secured $5M in debt financing from Silicon Valley Bank, financial partner to technology and life science companies of all sizes worldwide. CardioFocus will use the new financing to initiate its pivotal trial in the United States and to expand the commercialization of its products in Europe.

21 Mar 2011

LTC declares $0.50 per share quarterly dividend on Series F Cumulative Preferred Stock

LTC Properties, Inc. announced today that it had declared the quarterly cash dividend of $0.50 per share on the Company's 8.0% Series F Cumulative Preferred Stock. The dividend is payable on April 15, 2011 to stockholders of record on April 1, 2011.

21 Mar 2011